GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemostemix Inc (TSXV:HEM) » Definitions » Capex-to-Revenue

Hemostemix (TSXV:HEM) Capex-to-Revenue : 0.00 (As of Sep. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Hemostemix Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Hemostemix's Capital Expenditure for the three months ended in Sep. 2024 was C$0.00 Mil. Its Revenue for the three months ended in Sep. 2024 was C$0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.


Hemostemix Capex-to-Revenue Historical Data

The historical data trend for Hemostemix's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hemostemix Capex-to-Revenue Chart

Hemostemix Annual Data
Trend May14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Hemostemix Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24 Sep24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Hemostemix's Capex-to-Revenue

For the Biotechnology subindustry, Hemostemix's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hemostemix's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemostemix's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Hemostemix's Capex-to-Revenue falls into.



Hemostemix Capex-to-Revenue Calculation

Hemostemix's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0
=N/A

Hemostemix's Capex-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hemostemix  (TSXV:HEM) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Hemostemix Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Hemostemix's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Hemostemix Business Description

Traded in Other Exchanges
Address
707 - 7th Avenue SouthWest, Suite 1150, Calgary, AB, CAN, T2P 3H6
Hemostemix Inc is a biotechnology company. The company's principal business activity is developing, manufacturing, and commercializing blood-derived cell therapies for medical conditions. The Company's technology is a platform for developing autologous cell therapies to treat vascular diseases. The Company's clinical stage consists of ACP-01, autologous cell therapy for the treatment of critical limb ischemia.
Executives
Thomas Smeenk Director
Peter Alan Lacey Director
Loran Swanberg Director
Blake Wood 10% Security Holder
Ravi Jain Senior Officer

Hemostemix Headlines

No Headlines